HC Wainwright & Co. Maintains Buy on Regulus Therapeutics, Raises Price Target to $10

Benzinga · 06/25/2024 10:48
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Regulus Therapeutics (NASDAQ:RGLS) with a Buy and raises the price target from $9 to $10.